Results 131 to 140 of about 688 (142)

Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use

Gynecological Endocrinology, 2021
Santiago Palacios
exaly  

Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

Gynecological Endocrinology, 2004
E M Rutanen
exaly  

Vulvar vestibular effects of ospemifene: a pilot study

Gynecological Endocrinology, 2018
Filippo Murina, Stefania di Francesco
exaly  

Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents

European Journal of Medicinal Chemistry, 2014
Sanjeev Dhawan, Manoj Pandey, Arun K Sharma   +2 more
exaly  

Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice

Journal of Steroid Biochemistry and Molecular Biology, 2005
Laurel A. Beckett, Gregory T Würz, Jeffrey P Gregg   +2 more
exaly  

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

Journal of Women's Health, 2018
JoAnn Pinkerton, Corrado Altomare, James A Simon   +2 more
exaly  

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy

Climacteric, 2015
Nick Panay, Rossella E Nappi, Camil Castelo-Branco   +2 more
exaly  

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial

Climacteric, 2015
R C Rosen, S A Kingsberg, G Constantine
exaly  

Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations

Drug Metabolism and Drug Interactions, 2013
Miia Turpeinen, Olavi Pelkonen, Ari Tolonen   +2 more
exaly  

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

Journal of Bone and Mineral Metabolism, 2006
Marjo Tuppurainen, Risto Lammintausta, Jorma Heikkinen   +2 more
exaly